Researchers at the University of California, Los Angeles (UCLA), in collaboration with pathologists from Hadassah Hebrew ...

Fortunately, eight days after surgery, I received the pathology report and was elated to read that it was an oncocytoma ...

NEW YORK — Alpenglow Biosciences has partnered with digital pathology lab PathNet to develop 3D pathology-based diagnostics for prostate and bladder cancers, the companies said on Thursday.

Alpenglow Biosciences, the leader in clinical-grade 3D digital pathology and AI-powered spatial analytics, and PathNet, one of the nation’s foremost pathology laboratories and largest ...

Xencor, Inc. , a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced corporate priorities and 2026 pipeline ...

Dear A.K.: Ogilvie syndrome is acute pseudo-obstruction of the colon. It is considered pseudo-obstruction because it looks ...

The University Hospital Zurich (USZ) is one of Europe’s leading academic medical centers, offering cutting-edge clinical care and internationally recognized diagnostic expertise. The Department of ...

A novel tumor suppressor, BATF2, can be silenced by factors in the tumor microenvironment, leading to a reduced immune ...

A novel tumor suppressor, BATF2, can be silenced by factors in the tumor microenvironment, leading to a reduced immune response in five preclinical models of head and neck cancer, according to ...

Urological malignancies, including prostate, bladder, renal, and testicular cancers, represent a major global health burden and display remarkable ...

Thyroid cancer is the most common endocrine cancer, affecting more people each year as detection rates continue to rise.

Researchers used a panel to assess the presence of circulating tumor DNA in plasma samples and detected changes in genes related to the development of adenocarcinoma that indicated both actionability ...